Details for Patent: 11,654,139

Which drugs does patent 11,654,139 protect, and when does it expire?

Patent 11,654,139 protects JUBLIA and is included in one NDA.

This patent has twelve patent family members in six countries.

Summary for Patent: 11,654,139

Title:	Anti-infective methods, compositions, and devices
Abstract:	The present invention provides methods for treating onychomycosis. In certain embodiments, the methods comprise comprising applying a pharmaceutically acceptable formulation containing 10% efinaconazole once a day for a treatment period of at least 36 weeks to the treatment area of an onychomycosis patient (a) without debriding the nail or nail-associated tissue initially or during the treatment period and/or (b) without removing the formulation from the treatment area during the treatment period. In certain embodiments, the formulation also comprises, water, cyclomethicone, diisopropyl adipate, alcohol, C12-15 alkyl lactate, butylated hydroxytoluene, citric acid anhydrous, and disodium edetate.
Inventor(s):	Radhakrishnan Pillai, Gordon Dow
Assignee:	Bausch Health Ireland Ltd
Application Number:	US17/062,973
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 11,654,139

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bausch	JUBLIA	efinaconazole	SOLUTION;TOPICAL	203567-001	Jun 6, 2014	AB	RX	Yes	Yes						TOPICAL TREATMENT OF ONYCHOMYCOSIS OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES

International Family Members for US Patent 11,654,139

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2931144
Canada	3052643
China	105848719